Literature DB >> 31017228

Serum pyrazinamide concentrations in patients with pulmonary tuberculosis.

Stefania de Medeiros Araujo Lucena1, Carlos Augusto Abreu Alberio2, Ana Carla Godinho Pinto3, José Luiz Fernandes Vieira2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31017228      PMCID： PMC6733741          DOI： 10.1590/1806-3713/e20180254

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN： 1806-3713            Impact factor:   2.624


× No keyword cloud information.
  3 in total

Review 1.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

2.  Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.

Authors:  Jong Sun Park; Jae-Yeon Lee; Yeon Joo Lee; Se Joong Kim; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Junghan Song; Jae Ho Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

3.  Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.

Authors:  Maxwell T Chirehwa; Helen McIlleron; Roxana Rustomjee; Thuli Mthiyane; Philip Onyebujoh; Peter Smith; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191
  3 in total
  1 in total

1.  Tuberculosis series 2019.

Authors:  Denise Rossato Silva; Giovanni Battista Migliori; Fernanda Carvalho de Queiroz Mello
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.